BLOW UP the competition with the best of class Power & Endurance
Pre-Workout featuring Intensive Pump Technology. BLOW UP is a novel fast
acting pre-workout dietary supplement utilizing patented liposomal
delivery system for fast acting bronchodilation and vasodilation to
amplifying oxygen cascade and maximize training focus, intensity and
endurance.Ingredients included in BLOW UP have been scientifically proven to produce the following physiological effects:
- Increased heart ejection volume
- Amplified mitochondrial activity
- Surged muscle fiber contraction tension
- Sharpened mental alertness
- And much more
- Maximize VO2 Max
- Drastically intensify focus
- Enable Insane training intensity
- Dramatically improve endurance
- Bodybuilding, Fitness & Cross Fit
- Endurance sports (triathlon, cycling, running, etc.)
- Combat sports (MMA, boxing, karate, taekwondo, muay thai, jiu jitsu, judo, etc.)
- Team sports (football, hockey, soccer, bastekball, etc.)
- Any other physically demanding activity
Science behind BLOW UP Powerful effect
Oxygen availability (proportional to VO2 Max) increases performance
VO2 is a mean to quantify the amount of oxygen availability. There is a direct relationship between the VO2 Max and Performance.
Factors influencing VO2 Max
• ↑Lung capacity
• ↑Blood volume
• ↑Maximum heart rate
• ↑Red blood cell count
• ↑Concentration of hemoglobin
• ↑Heart ejection volume
BLOW UP forcefully increases VO2 Max by powerfully increasing all of the above factors.
Mitochondrial activity, another limiting factor of performance
Another factor significantly influencing performance is the amount of
ATP which can be produced in mitochondria, which is directly related to
BLOW UP® also effectively increases mitochondria activity.
BLOW UP® forcefully increases ALL parameters positively effecting oxygenation
Due to these cumulative effects, BLOW UP® drastically affects performance.
Higher bioavailability of active ingredients due to superior delivery system
BLOW UP® has been designed using WARMEDS unique patented
sublingual liposomal delivery system which increases by tens of folds
the absorption of each and all active compounds
Table 1: Estimated values, based on scientific literature and comprehensive analysis1
(%) with Oral
(%) with BLOW UP® Liposome
# fold increase
% bioavailability increase
Why other vendor’s formulas don’t work?
Most phytochemicals, including all the ones included in BLOW UP® and
listed below are either hydrophobic and poorly absorbed, or water
soluble but highly metabolized. This means that these compounds are very
poorly absorbed and/or destroyed in the intestine and liver before they
ever reach their intended destination. Below are the estimated range of
bioavailability you can expect with each ingredient when orally
lipophilic, poorly absorbed, and highly metabolized, and therefore very
little is bioavailable when orally delivered2
Although a significant proportion of synephrine is absorbed, nearly 97% of it is metabolized by the liver and other organs3, resulting in less than 3% bioavailability of the compound in the bloodstream
● Mucuna Pruriens
extract (L-dopa 98 %) containing highly hydrophobic actives which
greatly diminishes the compound’s absorption. After absorption, the
compound is extensively metabolized. Mucuna Pruriens therefore has a
very high variability in oral absorption, as well as a short half-life4.
When orally administered as a drug, it requires the co-administration
of another compound called carbidopa to slow its metabolism5.
has high absorption
variability both between users and even intraday in the same user, as
well as a rapid clearance (half-life of approximately 15-30 mins) after
oral absorption, leading to high variability of response.
● Muira puama
puama extract has highly hydrophobic compounds and these are very poorly absorbed
● Ginseng extract
Hydrophobic ginsenoside oral bioavailability is so low that it is virtually negligible
Why liposomal delivery work so well?
Traditional liquid liposomes have been shown to increase the bioavailability of lipophilic compounds by 20-50%6 or more. Because they are highly solubilized and stable in lipid emulsion7, compounds like Forskolin are highly bioavailable (estimated to >70%) when administered using liposome8.
Because it integrates all the latest and greatest technologies (i.e.:
superior carrier, multi lamellar, solid state desiccation, etc.) in
liposome science, WARMEDS® is the only company with the rights to use
the patented solid state liposome technology capable of producing
estimated yields up to 70-90% bioavailability, depending on compound9. More about the delivery system
Directions of use: Adults 18 and over: Let one tablet dissolve
under tongue and swallow 10 minutes prior to training. Do NOT exceed
recommended dose or take more than 1 tablet in a 24-hour period. Do not
use within 5 hours of alcohol consumption prior to or after use.
BLOWUP COMES WITH A LIMITED MONEY BACK GUARANTEE. IF YOU ARE NOT 100%
SATISFIED WITH BLOWUP EFFECTS AFTER ONE WEEK RETURN THE UNUSED PRODUCT
WITH A PROOF OF PURCHASE FOR A FULL REFUND. Minimal unused portion must
is 20 tablets. Maximum of 1 refund per household.
may vary between individuals. These statements have not been evaluated
by the Food and Drug Administration. This product is not intended to
diagnose, treat, cure, or prevent any disease.
product contains powerful naturally-derived ingredients that can
potentially interact with certain foods, medications and other
supplements. THIS PRODUCT IS NOT FOR USE BY PERSONS WITH A MEDICAL
CONDITION; IT IS NOT INTENDED FOR USE BY PERSONS UNDER THE AGE OF 18; OR
BY PREGNANT OR LACTATING WOMEN. Consumer is responsible and assumes all
risks, liabilities and consequences related to the use of this product,
including compliance with the rules and regulations of all governing
bodies or other entities having jurisdictions over any sport or athletic
activity in which he or she may participate, as well as all career
regulations. Always consult a physician or licensed qualified healthcare
professional before using this product. This product is not for people
with cardiovascular diseases, blood pressure problems, head injuries or
other medical diseases or disorders. Consult your physician prior to use
if you have a medical condition including but not limited to heart,
kidney, liver, or thyroid disease, psychiatric or epileptic disorders,
difficulty urinating, diabetes, high or low blood pressure, cardiac
arrhythmia, recurrent headaches, enlarged prostate or glaucoma. Anyone
suffering seizure disorders, epilepsy or Parkinson's type disorders
should consult a physician prior to use. Do not take any medication,
especially other cardiovascular system medications, antibiotics,
antihistamines, benzocaine and lidocaine or other drugs. Do not take
with other supplements products designed to increase nitric oxide levels
or products containing yohimbine or over 75mg of niacin per serving.
Avoid alcohol consumption within 5 hours before and after taking.
Discontinue use immediately if you experience one or more of the
following: dizziness, light-headedness, severe headache, low blood
pressure, rapid heartbeat, shortness of breath. Discontinue use 2 weeks
prior to a surgery. KEEP OUT OF THE REACH OF CHILDREN.
estimates are based on scientific evaluation of comparable or related
systems, and are intended to be best guest estimates of the
bioavailability of our delivery system. These values cannot be taken to
be exact for any substance or particular methods of use. They are
presented only for information purposes.
metabolism via UDP glucuronosyltransferase: a barrier to oral
bioavailability of phenolics, J. Pharm Sci. 2011 Sep; 100(9): 3655–3681.
Published online 2011 Apr 11. doi: 10.1002/jps.22568, , Baojian Wu,
Kaustubh Kulkarni, Sumit Basu, Shuxing Zhang, and Ming Hu
Pharmacokinetics and metabolism of 3H-synephrine (author's transl),
Arzneimittelforschung. 1978;28(12):2326-31, [Article in German]
Hengstmann JH, Aulepp H.
4 The pharmacokinetics of
intravenous and oral levodopa in patients with Parkinson's disease who
exhibit on-off fluctuations, Br. J. clin. Pharmac. (1986), 22, 429-436,
R. J. HARDIE*', S. L. MALCOLM2, A. J. LEES1, G. M. STERN1 & J. G.